NUCLEA BIOTECHNOLOGIES, INC FUNDS PAUL M. DOWD CHAIR IN MOLECULAR ONCOLOGIC PATHOLOGY AT DANA-FARBER CANCER INSTITUTE
Pittsfield, MA – Nuclea Biotechnologies, Inc. yesterday announced that it will establish the Paul M. Dowd Chair in Molecular Oncologic Pathology in honor of the Berkshire County Jimmy Fund Council, creating Dana-Farber Cancer Institute’s first Chair of Molecular Oncologic Pathology. Dr. Massimo F. Loda will serve as the Chair’s first incumbent. The endowed position will help to further advance Dana-Farber’s and Dr. Loda’s research into the prevention, detection, and treatment of cancer.
Originally from Michigan, Paul Dowd first came to Pittsfield in 1966 as a pitcher for the Pittsfield Red Sox minor league club. He lived in the city for 35 years, and left an indelible mark as a Marine, City Councilor, and Little League coach. Along the way, Paul Dowd became a champion of cancer research. In 1981 he founded the Berkshire County Council of the Jimmy Fund, and he continues to serve as its president.
“You cannot overestimate Paul Dowd’s contribution to the fight against cancer,” said Patrick Muraca, President & CEO of Nuclea Biotechnologies. “For three decades, Paul worked to raise awareness of the disease and raise money for the cure. He inspired generations of folks here in the Berkshires to not only contribute to the cause financially, but also to dedicate their careers to finding a cure. We are so thrilled to be able to honor him in this way, and to support the groundbreaking research that Dr. Loda and his team continue to produce at Dana-Farber.”
Dr. Loda joined Dana-Farber Cancer Institute in 1998, and currently directs the Center for Molecular Oncologic Pathology. He is also a senior pathologist at Brigham and Women's Hospital. Dr. Loda established and was the scientific director of the In Situ Hybridization and the Human Prostate Cancer Core Facilities at the Dana-Farber/Harvard Cancer Center. Since 2006, he has partnered with Nuclea to conduct research into the biomarkers and protein signatures that can help detect prostate, breast, and other cancers.
“I am truly honored to be chosen for the Paul M. Dowd Chair in Molecular Oncologic Pathology at Dana-Farber Cancer Institute,” said Dr. Loda. “Nuclea’s generosity will enable us to further the important scientific research that happens here every day, and to bring us closer to our mutual goal of curing all forms of cancer. This chair, which acknowledges Mr. Dowd’s contributions to the fight against cancer and dedicated leadership at the Berkshire County Jimmy Fund Council, will serve as an inspiration to all of us here at Dana-Farber. I am tremendously grateful for this opportunity”.
“We are so pleased that Nuclea has chosen to honor Paul Dowd and the entire Berkshire County Jimmy Fund Council by creating the Paul M. Dowd Chair,” said Suzanne Fountain, Assistant Vice President/Director of the Jimmy Fund. “Paul has made an indelible mark on all of us here at Dana-Farber and along with Nuclea has been a tremendously important partner in our fight against cancer. We look forward to many more years of working together to provide world-class care to our patients while performing cutting-edge scientific research and we are incredibly grateful to Pat, Paul, and the whole Jimmy Fund Council.”
Nuclea Biotechnologies, Inc is headquartered in Pittsfield, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDL”) which has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBM”) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBT”) which develops novel therapeutics.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Facebook: www.facebook.com/danafarbercancerinstitute and on Twitter: @danafarber.
About the Jimmy Fund
The Jimmy Fund (www.JimmyFund.org) solely supports Boston’s Dana-Farber Cancer Institute, raising funds for adult and pediatric cancer care and research to improve the chances of survival for cancer patients around the world. It is an official charity of the Boston Red Sox, as well as the official charity of the Massachusetts Chiefs of Police Association, the Pan-Massachusetts Challenge, and the Variety Children's Charity of New England. Since 1948, the generosity of millions of people has helped the Jimmy Fund save countless lives and reduce the burden of cancer for patients and families worldwide. Follow the Jimmy Fund on Facebook: www.facebook.com/thejimmyfund and on Twitter: @TheJimmyFund.
MassBio Membership gives you:
Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members.
Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.
MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.
Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.
Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.
Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!
Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.